¹ Protocol on Establishing a National Disease

² Registry – Swiss Pediatric Inflammatory

³ Brain Disease Registry

- 4 Swiss Pediatric Inflammatory Brain Disease Registry
- 5
- 6 Lorena Freya Hulliger¹, Anne Tscherter¹, Claudia Kühni¹, Sandra Bigi^{1,2},
- 7 ¹Institute of Social and preventive medicine, University of Bern, Bern, Bern, Switzerland
- 8 ²Department of Neuropediatrics, Lucerne cantonal hospital, Children's hospital, Lucerne, Lucerne,
- 9 Switzerland

10 Metadata

11 Funding

- 12 This project is funded by the following organizations: Swiss Multiple Sclerosis Society, Roche Pharma
- 13 (Switzerland) Ltd, Novartis Pharma Schweiz AG, and Sanofi-Aventis (Schweiz). The funders had no role in
- 14 the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

15 Competing interests

16 None of the authors have any potentially competing interest to declare.

17 Data availability

- 18 This manuscript is purely technical and does not include any data beyond number of identified potential
- 19 study participants and number of signed informed consent forms.

20 Abstract

21 Background

- 22 Pediatric-onset inflammatory brain diseases are a group of potentially life-threatening central nervous
- 23 system disorders. Overall, pediatric-onset inflammatory brain diseases are rare and therefore difficult to
- 24 study. Patient registries are well suited to study the natural history of (rare) diseases and have markedly
- 25 advanced the knowledge on pediatric-onset inflammatory brain diseases in other countries. Following
- 26 their example, we established a national pediatric-onset inflammatory brain disease registry in
- 27 Switzerland (Swiss-Ped-IBrainD).
- 28 Aims
- 29 The Registry aims to describe epidemiology, demographics, diagnostics, management, and treatment,

30 since these areas remain understudied in Switzerland. Additionally, we want to promote research by

- fostering the knowledge exchange between study centers and setting up studies such as national quality
- 32 of life surveys. We further aim to facilitate the access to national and international studies for patients
- 33 with a pediatric-onset inflammatory brain disease living and/or treated in Switzerland.

34 Methods

35 The Swiss-Ped-IBrainD is a multicentric, population-based, observational cohort study (IRB number:

36 2019-00377) collaborating with 11 neuropediatric centers in Switzerland. Patient screening, information

37 and recruitment is mainly conducted by the local principal investigators. The data collection is organized

38 centrally by the Executive Office of the registry. The collected data is purely observational. Medical

- 39 records are the primary data source. All patients who have been diagnosed with a pediatric-onset
- 40 inflammatory brain disease since 2005 are eligible. We aim to include all pediatric-onset inflammatory
- 41 brain disease patients living and/or treated in Switzerland who meet the inclusion criteria. Considering
- 42 existing literature and our single-center experience we anticipate 300-400 eligible patients.

43 Status

- 44 Currently, all 11 neuropediatric centers have been initiated and are recruiting. As of the first of May
- 45 2023, we have identified 275 eligible participants and obtained informed consent from 101 patients
- 46 and/or families. None of the informed patients and/or families have refused participation.

Pediatric-onset inflammatory brain diseases (IBrainDs) are rare central nervous system (CNS) diseases

47 Introduction

48

49	with the potential to cause life-threatening conditions. Often, patients experience an acute initial phase
50	with neurological symptoms including focal neurological deficits, cognitive and/or behavioral
51	dysfunctions, seizures, hemiparesis, and ataxia (1, 2).
52	IBrainDs may be primary (idiopathic) or secondary in origin, e.g., as part of a systemic disease or
53	infection (1-5). Irrespective of the origin, IBrainD pathology is characterized by immune cell activation,
54	inflammation, cytokine, and/or antibody production. Specific inflammatory pathways target different
55	structures in the CNS (2, 6). Such structures may be certain segments of blood vessels and neurons or
56	CNS proteins such as myelin, cell surface receptors, channels, or enzymes (6). Based on either the
57	affected structures or the disease mechanism, IBrainDs may be classified as demyelinating, antibody-
58	associated, T-cell mediated, granulomatous, or CNS vasculitis.
59	Overall, pediatric-onset IBrainDs are rare. Incidences are only known for a few subgroups, such as
60	demyelinating diseases 0.05-2.85/100'000 persons/year (7-14). Other IBrainDs are presumed to occur
61	even less frequently. However, epidemiological data, particularly on children, are lacking.
62	Rare diseases are inherently difficult to study. Their investigation requires special efforts and
63	appropriate instruments. Patient registries are well suited to study the natural history of (rare) diseases;
64	the Canadian pediatric demyelinating disease registry and BrainWorks – a Canadian registry for pediatric
65	IBrainD patients – have markedly advanced the knowledge on IBrainDs in children (2, 6). Additionally,
66	they have increased awareness and consecutively helped to improve the care of this vulnerable
67	population.

Following their example, a national pediatric-onset IBrainD registry (Swiss-Ped-IBrainD) was founded in
2019.

70 The primary focus of the Swiss-Ped-IBrainD is on the understudied areas in this field, such as

epidemiology, health care management in general (and the diagnostic process in particular), as well as

72 long-term patient outcomes.

73 Epidemiological data such as prevalence, incidence, or prognostic data are invaluable for recognition of

74 pediatric-onset IBrainDs by the healthcare system. This may favor future policymaking which addresses

75 pediatric-onset IBrainDs.

76 Pediatric-onset IBrainDs are often diagnosed with a significant delay, which entails a delay in treatment

initiation. Optimizing the diagnostic process is one of our priorities since starting treatment early

improves disease outcomes (3, 5, 6, 11) – particularly in demyelinating and antibody-mediated diseases.

79 Researching the clinical phenotypes of pediatric-onset IBrainDs and gathering information on the

80 diagnostic workup will help to differentiate the diseases and expedite the diagnosis.

81 In an acute phase the treatment of IBrainDs is directed at controlling the inflammation. Following the

82 acute intervention, many patients receive specific immunomodulatory treatment depending on the

83 inflammatory pathways of the underlying IBrainD (6). Despite appropriate treatment, some children

84 develop functional deficits (3, 11). We will assess these functional deficits and other outcomes of

85 pediatric-onset IBrainD patients and hope to identify relevant factors that may be implemented in new

86 treatment guidelines.

87 Furthermore, the registry should enable patients with pediatric-onset IBrainDs to participate in

88 international clinical studies for e.g., new drugs or new therapeutic regimens. Until now, these patients

89 have rarely had the opportunity to participate in international studies – they were at a disadvantage

90 compared to patients from countries with centralized registration such as France or Italy.

- 91 Through the Swiss-Ped-IBrainD registry and its linkage with other rare disease registries, we also expect
- 92 to achieve high enough case numbers for statistically significant results.

93 Materials and methods

94 Main aims

- 95 The Swiss-Ped-IBrainD registry has three main aims.
- 96 Firstly, to provide detailed and comprehensive health reporting on pediatric-onset IBrainDs in
- 97 Switzerland. The reporting includes but is not limited to the following areas of interest: epidemiology,
- 98 demographics, diagnostics, management, and treatment.
- 99 Secondly, to promote research by cultivating a regular exchange between the study centers and
- 100 providing investigators with access to the high-quality structural data collected by the registry.
- 101 Thirdly, to facilitate access to national and international studies for pediatric IBrainD patients living
- 102 and/or treated in Switzerland.

103 Procedure

- 104 The Swiss-Ped-IBrainD Registry is a multicentric, population based, observational cohort study. The
- 105 eleven neuropediatric centers in Switzerland shown in Figure 1 have agreed to participate.
- **106** Figure 1: Participating Departments/Divisions of Neuropediatrcs, Child Neurology and Neuropsychology
- 107 We expect to detect close to 100% of new pediatric-onset IBrainD patients. Since pediatric-onset
- 108 IBrainDs are severe conditions requiring expert care, most patients in Switzerland will seek help at or be
- 109 referred to one of the participating specialized centers. Child neurologists in private practices in
- 110 Switzerland do not treat IBrainD patients themselves (15); missing new patients with a pediatric-onset
- 111 IBrainD is therefore highly unlikely.

112	Patient screening is conducted by the principal investigators (PIs) of the study centers. They compile a
113	screening list and inform all regularly seen, eligible patients of the registry. Patients who do not pay
114	regular visits to the centers (due to various reasons including transition to adult care, moving, and
115	treatment conclusion) may be informed by letter. All informed patients are invited to consent to study
116	participation by means of signing the informed consent form. If the patient is underage, their
117	parent(s)/guardian(s) must also sign the informed consent form. Recruitment has started on the 1 st of
118	November 2020. As is typical for a medical registry, recruitment is open-ended and therefore has no
119	fixed end date.
120	The signed consent form allows us to collect all of the patient's data (including identifying data) as
121	defined in the case report forms. If patients or their families choose not to consent, we can still collect a
122	de-identified minimal dataset including diagnosis, year of diagnosis, year of birth, sex, status (dead or
123	alive) and cause of death, if applicable. This procedure has been approved by the local ethics committee
125	anver and eause of death, if applicable. This procedure has been approved by the local earlies committee
124	to ensure the completeness of the epidemiological data.
124	to ensure the completeness of the epidemiological data.
124 125	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source.
124 125 126	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis
124 125 126 127	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric
124 125 126 127 128	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric IBrainD patients are recruited continuously. Their data as well as the follow-up data of formerly
124 125 126 127 128 129	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric IBrainD patients are recruited continuously. Their data as well as the follow-up data of formerly diagnosed patients are collected and updated regularly (prospective).
124 125 126 127 128 129 130	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric IBrainD patients are recruited continuously. Their data as well as the follow-up data of formerly diagnosed patients are collected and updated regularly (prospective). The data collection itself is centrally organized by the Executive Office, which is the operational arm of
124 125 126 127 128 129 130 131	to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric IBrainD patients are recruited continuously. Their data as well as the follow-up data of formerly diagnosed patients are collected and updated regularly (prospective). The data collection itself is centrally organized by the Executive Office, which is the operational arm of Swiss-Ped-IBrainD and is located at the Institute of Social and Preventive Medicine (ISPM) at the

- 135 This includes establishing access to source documents and case report forms for the Executive Office
- and the transformation of this into a standardized process.
- 137 To promote joint research and advance patient management the Task Force on Patient Care and
- 138 Management was founded. This working group meets bimonthly and is comprised of all PIs as well as
- additional experts in the field (neuropsychologists and neuroradiologists).
- 140 The Swiss-Ped-IBrainD further provides the basis for national surveys, since questionnaire studies in line
- 141 with the objectives of the Swiss-Ped-IBrainD are covered by the ethical approval. We are currently
- 142 preparing the first questionnaire on patient/family perceptions of the diagnostic process and quality of
- 143 life.

144 Study Population

- 145 Regarding the target population, we aim to include all pediatric-onset IBrainD patients living or treated
- in Switzerland who have been diagnosed since 2005 (Swiss population \leq 33 years of age: 3'260'287
- 147 (Statistik 2010)). Because epidemiological data on pediatric-onset IBrainDs is scarce, the number of
- eligible patients is merely a rough estimate. Incidences between 0.05-2.85/100'000 persons/year (7-14)
- have been reported for demyelinating diseases of the CNS and 0.04-0.33/100'000 persons/year (16, 17)
- 150 for other IBrainDs such as pediatric-onset anti-NMDA receptor encephalitis. Considering these numbers
- and our single center experience we anticipate 300-400 eligible patients.

152 Inclusion criteria

- 153 Patients living and/or treated in Switzerland diagnosed since 2005 with one of the pediatric-onset
- 154 IBrainDs listed in Table 1.

Table 1: Pediatric-onset inflammatory brain diseases to be included in the Swiss Pediatric Inflammatory Brain Disease Registry.
 The list of the included diagnoses might evolve over time given the active research in the field and validation of new techniques for diagnosis.

Disease Family	Diagnosis
----------------	-----------

Demyelinating	Optic neuritis	
	Transverse myelitis	
	Acute disseminated encephalomyelitis	
	Multiple sclerosis	
	Neuromyelitis optica spectrum disorders	
Antibody associated	Anti-NMDA-R	
	Anti-GAD65	
	Anti-AMPA-1/2	
	Anti-Lgi-1	
	Anti-CASPR-2	
	Anti-GABA-1/2	
	Onconeuronal antibodies	
	Hashimoto encephalopathy	
T-cell mediated	Rasmussen's encephalitis	
Other	CNS Vasculitis	
	CNS Sarcoidosis	
	CNS Lupus	

158

159 Exclusion criteria

160 Patients with neurological symptoms due to infectious diseases of the CNS or congenital infections (such

as TORCH, peripheral facial palsy), patients with genetic metabolic causes of central demyelinating

diseases and patients with neurological symptoms due to Guillain-Barré-Syndrome will be excluded from

163 participation.

164 Organization

- 165 Swiss-Ped-IBrainD has two main bodies: the Steering Board and the Executive Office.
- 166 The Steering Board consists of medical specialists, mainly pediatric neurologists, and has an elected
- 167 President and Vice-President. It supervises the Executive Office and sets the direction.
- 168 The Executive Office, located at the ISPM, consists of the Co-Heads (Swiss-Ped-IBrainD Legal
- 169 Representative and Clinical Lead), the Project Manager, the Data Manager and other team members. It
- 170 manages the database, the variables, the archived documents, and the information on organization
- 171 rules.

172 Other closely linked structures are the participating clinics and the Task Force on Patient Care and

173 Management.

- 174 The main task of the participating clinics is to recruit patients and provide data to the Swiss-Ped-IBrainD.
- 175 The main task of the Task Force is to discuss complex cases, establish standards of care and work on
- 176 pressing issues in the field of pediatric-onset IBrainDs. Figure 1 shows the organization of the Swiss-Ped-
- 177 IBrainD and its associated structures.
- Figure 2: Organizational structure of the Swiss Pediatric Inflammatory Brain Disease Registry; PM: Project management; DM:
 Data management

180 Ethics statement

- 181 This project was approved by the cantonal ethics committee of Bern (IRB number: 2019-00377) as well
- as the ethics committees of Northwest and Central Switzerland, Ticino, Zürich, Geneva, Vaud, and East
- 183 Switzerland, which cover the 11 study centers. It is and will be conducted in accordance with the
- 184 protocol, the Declaration of Helsinki (18), the principles of Good Clinical Practice (19), the Human
- 185 Research Act (20) and the Human Research Ordinance (21) as well as other locally relevant regulations.
- 186 The Swiss-Ped-IBrainD will further adhere to the recent recommendations for health-related registries
- 187 elaborated by the National Association for Quality Development in Hospitals and Clinics, Swiss Medical
- 188 Association, Swiss Hospitals Association, Swiss Academy of Medical Sciences, and University Medicine
- 189 Switzerland (22). These recommendations serve as basis for quality assurance of registries.

190 Data management

- 191 We collect and archive all personal, medical, and questionnaire data as well as digitalized documents of
- 192 the project in a dedicated electronic data capturing system (REDCap ISPM UniBe). The database
- 193 complies with all requirements for data security and protection.

194 Statistical analysis plan

- 195 Since the registry has no designated endpoint, we will continuously analyze the collected data and
- 196 update results according to our evolving objectives.
- 197 Initially, descriptive statistics (mean and standard deviation, median and range, summary tables and
- simple graphics) will serve to characterize pediatric-onset IBrainD patient population of Switzerland.
- 199 Subsequently, we plan to investigate between-group differences with tests such as t-tests, chi-squared,
- 200 Wilcoxon-Mann, and Fisher's exact depending on the variables in question.
- 201 For more advanced analyses including associations between factors, we will use regression modelling
- 202 (logistic, linear, Poisson). For follow-up data we will apply statistical methods appropriate for
- 203 longitudinal data such as cox and Poisson regression or Kaplan-Meier survival curves.
- 204 We also intend to supplement our datasets with data from relevant routine data and other registries.
- 205 This allows conducting case-control studies or cohort-based studies about causes and the long-term
- 206 course of pediatric-onset IBrainDs.
- 207 For all analyses we will use STATA (STATA Corp LP, Texas USA) and R (R Foundation for Statistical
- 208 Computing, Vienna, Austria) or comparable statistical software.

209 Safety considerations

- 210 The project participation entails minimal risks and burdens (category A). We do not expect any safety
- issues and therefore refrain from implementing protective measures.

212 Current status

- 213 Currently, all 11 neuropediatric centers have been initiated and are recruiting. As of the first of May
- 214 2023, we have identified 275 eligible participants and obtained 101 informed consents from patients
- and/or families. None of the informed patients and/or families have refused participation.

216 Dissemination plan

- 217 Results of this project will be published in scientific journals and presented at scientific conferences.
- 218 Authorship will be handled according to the ICMJE (www.icmje.org). Ongoing studies and short
- summaries of the latest news are published on the project website. We will generate annual reports of
- the Swiss-Ped-IBrainD.

221 Discussion

222 Potential problems and limitations

223	We want to reach completeness – meaning we want to collect data from the entire target population.
224	This is challenging since some patients, especially those with mild IBrainDs, may no longer require
225	continued medical care. They are therefore difficult to find and reach (selection/recruitment bias).
226	However, we will exploit all available and legal measures to recruit as many patients as possible. To
227	directly address and minimize the effect of selection/recruitment bias we will collect the minimal
228	dataset from all identified patients after they have been informed.
229	Misclassification may be a further limitation. To reduce misclassification, we rely on an international
230	classification system and results from biopsies, electrophysiological examinations, and specific
231	laboratory testing (e.g., presence of disease-identifying antibodies such as NMDA-R-AB or NMO-IgG).
232	Patients without a precise diagnosis will not be included. We will also run regular plausibility checks.
233	Missing data is a further limitation we foresee. To minimize data gaps in the medical history of the
234	patients, we have centralized the data collection; a member of the Executive Office regularly visits the
235	participating centers and collects patient data. These data-collection visits are also good opportunities
236	to resolve open queries and monitor recruitment. Regarding data from questionnaires, we will remind
237	patients to return their questionnaires. On the analysis level, we will use inverse probability weighting to
238	account for an eventual attrition bias (23). This procedure gives more weight to well-explained
239	observations (by baseline data) and thereby compensates for non-observed follow-up data. Missing data
240	may also be computed by multiple imputation, as done in previous studies (24).

241 Amendments and end of project

- 242 Substantial changes to the project set-up, the protocol and relevant project documents will be
- submitted to the responsible institutional review board for approval. This includes the distribution of
- 244 questionnaires to patients and families.
- 245 The project has no defined endpoint. However, the Swiss-Ped-IBrainD may be terminated or suspended
- 246 due to financial or personnel-related reasons.

247 Acknowledgements

248 We thank Lilianna Bolliger for important ground-laying work.

249 References

250 1. Cellucci T, Tyrrell PN, Twilt M, Soon GS, Yau I, Sheikh S, et al. Distinguishing features in the 251 presentations of childhood inflammatory brain diseases at a tertiary-care centre. Pediatric Rheumatology Online Journal. 2012;10(Suppl 1):A81. 252 253 Liu E, Twilt M, Tyrrell PN, Dropol A, Sheikh S, Gorman M, et al. Health-related quality of life in 2. 254 children with inflammatory brain disease. Pediatric Rheumatology Online Journal. 2018;16(1):73. 255 Smitka M, Bruck N, Engellandt K, Hahn G, Knoefler R, von der Hagen M. Clinical Perspective on 3. 256 Primary Angiitis of the Central Nervous System in Childhood (cPACNS). Frontiers in pediatrics. 257 2020;8:281. 258 Twilt M, Sheikh S, Benseler S. PReS-FINAL-2362: The spectrum of childhood inflammatory brain 4. diseases; an increasingly recognised field. Pediatric Rheumatology Online Journal. 2013;11(Suppl 259 260 2):P352. 261 5. Twilt M, Benseler SM. CNS vasculitis in children. Multiple sclerosis and related disorders. 262 2013;2(3):162-71. 263 Twilt M, Benseler SM. Childhood inflammatory brain diseases: pathogenesis, diagnosis and 6. 264 therapy. Rheumatology (Oxford, England). 2014;53(8):1359-68. 265 7. Metz I, Weigand SD, Popescu BF, Frischer JM, Parisi JE, Guo Y, et al. Pathologic heterogeneity 266 persists in early active multiple sclerosis lesions. Annals of neurology. 2014;75(5):728-38. 267 Pavone P, Pettoello-Mantovano M, Le Pira A, Giardino I, Pulvirenti A, Giugno R, et al. Acute 8. 268 disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics. 269 2010;41(6):246-55. 270 9. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS 271 demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011;77(12):1143-8. 272 Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KG, Eikelenboom MJ, 10. 273 et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. 274 Journal of neurology. 2012;259(9):1929-35. 275 Bigi S, Hladio M, Twilt M, Dalmau J, Benseler SM. The growing spectrum of antibody-associated 11. 276 inflammatory brain diseases in children. Neurology(R) neuroimmunology & neuroinflammation. 2015;2(3):e92. 277 278 Burton KLO, Williams TA, Catchpoole SE, Brunsdon RK. Long-Term Neuropsychological Outcomes 12. 279 of Childhood Onset Acute Disseminated Encephalomyelitis (ADEM): a Meta-Analysis. Neuropsychology 280 review. 2017;27(2):124-33. 281 Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic 13. 282 Review of the Literature. Journal of child neurology. 2019;34(12):705-12. 283 Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: A 14. 284 systematic literature review and meta-analysis. Multiple sclerosis and related disorders. 285 2020;44:102260. 286 Hofer S, Bauder F, Capone Mori A, Chan A, Dill P, Garcia-Tarodo S, et al. Management of Acute 15. 287 Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. Clinical and 288 Translational Neuroscience. 2021;5(2):17. 289 16. Giri YR, Parrill A, Damodar S, Fogel J, Ayed N, Syed M, et al. Anti-N-Methyl-D-Aspartate Receptor 290 (NMDAR) Encephalitis in Children and Adolescents: A Systematic Review and Quantitative Analysis of 291 Reported Cases. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de 292 l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent. 2021;30(4):236-48.

Ho AC, Chan SH, Chan E, Wong SS, Fung ST, Cherk SW, et al. Anti-N-methyl-d-aspartate receptor
encephalitis in children: Incidence and experience in Hong Kong. Brain & development. 2018;40(6):4739.

- 18. Association WM. World Medical Association Declaration of Helsinki: ethical principles for
 medical research involving human subjects. Jama. 2013;310(20):2191-4.
- 19. (ICH) ICfHoTRfPfHU. INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL
 PRACTICE E6(R2). 2016.
- 20. (KAV) SB. Bundesgesetz über die Forschung am Menschen (Humanforschungsgesetz, HFG;
 301 Human Research Act. 2013.
- 302 21. (KAV) SB. Verordnung über die Humanforschung mit Ausnahme der klinischen Versuche
- 303 (Humanforschungsverordnung, HFV): Human Research Ordinance. In: Gesundheit Bf, editor. 2013.
- Busch P, Heller R, Hofstetter A, Clerc V, Kern A, Nienhaus A, et al. Recommendations for the
 development and operation of health-related registries. 2.0 ed2019.
- Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding
 in Observational Studies. Multivariate behavioral research. 2011;46(3):399-424.
- 24. Dogaru CM, Strippoli MP, Spycher BD, Frey U, Beardsmore CS, Silverman M, et al. Breastfeeding
- and lung function at school age: does maternal asthma modify the effect? American journal of
- respiratory and critical care medicine. 2012;185(8):874-80.




Figure 1




Figure 2